Korsana Biosciences, Inc. Common Stock
KRSA
74 hedge funds and large institutions have $49.1M invested in Korsana Biosciences, Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 18 increasing their positions, 21 reducing their positions, and 17 closing their positions.
17% more capital invested
Capital invested by funds: $41.8M → $49.1M (+$7.28M)
10.77% more ownership
Funds ownership: 55.99% → 66.76% (+11%)
1% more funds holding
Funds holding: 73 → 74 (+1)
6% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 17
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
14% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SPC
Slate Path Capital
New York
|
+$609K |
| 2 |
MP
MFN Partners
Boston,
Massachusetts
|
+$479K |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$475K |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$346K |
| 5 |
AG
Artal Group
Luxembourg
|
+$255K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$952K |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$471K |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$379K |
| 4 |
Squarepoint
New York
|
-$372K |
| 5 |
MAP
Madison Avenue Partners
New York
|
-$361K |
KRSA Hedge Fund Activity: Q1 2020 in Review
74 of the 4,548 institutional investors tracked by Wall St. Rank reported a position in Korsana Biosciences, Inc. Common Stock (KRSA) for Q1 2020, worth a combined $49.1M — up 17% from $41.8M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new KRSA positions and 17 closed out — a net gain of 1 holder — while 18 added to existing stakes and 21 trimmed.
The largest buyer was Slate Path Capital, opening a new position worth an estimated $609K. The largest seller was Farallon Capital Management, exiting entirely with an estimated $952K sold.
- 74 institutional investors held Korsana Biosciences, Inc. Common Stock (KRSA) as of Q1 2020, up from 73 in Q4 2019.
- Funds reported $49.1M of Korsana Biosciences, Inc. Common Stock stock for Q1 2020, up 17% quarter-over-quarter.
- 18 funds opened new Korsana Biosciences, Inc. Common Stock positions in Q1 2020 and 17 closed out, a net change of +1 holder.
- The largest Korsana Biosciences, Inc. Common Stock buyer in Q1 2020 was Slate Path Capital, an estimated $609K added.
- The largest Korsana Biosciences, Inc. Common Stock seller in Q1 2020 was Farallon Capital Management, an estimated $952K sold.
Based on aggregated 13F filings for Q1 2020.